Catalyst Pharmaceuticals, Inc.CPRXNASDAQ
Loading
EBITDA Margin Over TimeExpanding
Percentile Rank100
3Y CAGR+4.2%
5Y CAGR+9.4%
Studio
Year-over-Year Change

EBITDA as a percentage of revenue

3Y CAGR
+4.2%/yr
Annual compound
5Y CAGR
+9.4%/yr
Recent deceleration
Percentile
P100
Near historical high
vs 5Y Ago
1.6x
Solid growth
Streak
2 yr
Consecutive growthExpanding
PeriodValueYoY Change
202554.50%+15.1%
202447.36%+57.6%
202330.06%-37.5%
202248.12%+28.9%
202137.33%+7.4%
202034.76%+11.6%
201931.16%+100.4%
2018-7051.44%-